Brief: BioCryst Reports Q3 2024 Financial Results And Provides Business Update
04/11/2024 14:31
Nov 4 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O :
* BIOCRYST REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE
* BIOCRYST PHARMACEUTICALS OUTLOOK 2024 TOTAL PRODUCT
REVENUE
GUIDANCE OF $443-$448 MILLION
* BIOCRYST PHARMACEUTICALS: CO IS CONFIDENT IT WILL ACHIEVE
A
FULL-YEAR OPERATING PROFIT IN 2024, NOT INCLUDING NON-CASH STOCK
COMPENSATION
Source text: ID:nGNX2wnF4G
Further company coverage: BCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026